title: Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
abstract: The t(5;17)/NPM-RARalpha is the second variant chromosomal translocation in acute promyelocytic leukemia (APL) to be characterized and also the second most plentiful variant translocation. So far, there is a lack of information on the effectiveness of arsenic trioxide (ATO) in relapsed APL with variant RARalpha chimera including t(5;17)/NPM-RARalpha. We report here a long-term survived APL patient with variant NPM-RARalpha fusion who relapsed four times and each time responded well to ATO or ATO-based re-induction therapy. The patient had received a total of more than 3,500 mg of ATO, but showed no obvious arsenic-related toxicities. This case illustrates the long-term efficiency and safety of ATO-based therapy not only in newly diagnosed APL, but also in relapsed APL including those with variant translocations.
authors.affiliation: Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Chen
authors.forename: Ling
authors.initials: L
authors.lastname: Gu
authors.forename: Chenyan
authors.initials: C
authors.lastname: Zhou
authors.forename: Xueqiang
authors.initials: X
authors.lastname: Wu
authors.forename: Ju
authors.initials: J
authors.lastname: Gao
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
authors.forename: Yiping
authors.initials: Y
authors.lastname: Zhu
authors.forename: Cangsong
authors.initials: C
authors.lastname: Jia
authors.forename: Zhigui
authors.initials: Z
authors.lastname: Ma
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D010087:Oxides / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; C120276:NPM-RARalpha protein, human; D015514:Oncogene Proteins, Fusion; D010087:Oxides; D000077237:Arsenic Trioxide
references.citation: Best Pract Res Clin Haematol. 2003 Sep;16(3):387-408
references.pmid: 12935958
references.citation: Blood. 1997 May 1;89(9):3354-60
references.pmid: 9129042
references.citation: Oncogene. 1999 Jan 28;18(4):1113-8
references.pmid: 10023688
references.citation: Int J Hematol. 2007 Oct;86(3):246-9
references.pmid: 17988991
references.citation: Blood. 2008 Mar 1;111(5):2505-15
references.pmid: 18299451
references.citation: Blood. 2009 Feb 26;113(9):1875-91
references.pmid: 18812465
references.citation: J Clin Oncol. 2001 Sep 15;19(18):3852-60
references.pmid: 11559723
references.citation: Blood. 2006 Apr 1;107(7):2627-32
references.pmid: 16352810
references.citation: Leukemia. 2002 Oct;16(10):1927-32
references.pmid: 12357344
references.citation: Am J Hematol. 2002 Aug;70(4):292-9
references.pmid: 12210810
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7
references.pmid: 19225113
references.citation: Blood. 2007 Dec 1;110(12):4073-6
references.pmid: 17712046
references.citation: Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Aug;25(4):430-3
references.pmid: 18683144